Invasive fungal infections in the pediatric population

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 3, 2011, Pages 275-278

  Lehrnbecher, Thomas ^a   Groll, Andreas H ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

children; diagnosis; epidemiology; mycoses; treatment

Indexed keywords

BETA GLUCAN; GALACTOMANNAN; POSACONAZOLE;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; POSTMARKETING SURVEILLANCE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

EID: 79952904034     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.1     Document Type: Review

References (37)

1. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. Invasive fungal infections in children. Pediatr. Infect. Dis. J. 28(8), 734-737 (2009).
2. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33(1), 23-32 (1996). (Pubitemid 26289847)
3. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 61(3), 259-265 (2010).
4. Levy O, Martin S, Eichenwald E et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability- increasing protein. Pediatrics 104(6), 1327-1333 (1999).
5. Yossuck P, Nightengale BJ, Fortney JE, Gibson LF. Effect of morphine sulfate on neonatal neutrophil chemotaxis. Clin. J. Pain 24(1), 76-82 (2008).
6. Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ. Therapy-induced alterations in host defense in children receiving chemotherapy. J. Ped. Hematol. Oncol. 19, 399-417 (1997). (Pubitemid 28076484)
7. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41(9), 1232-1239 (2005). (Pubitemid 41532664)
8. Zaoutis T, Walsh TJ. Antifungal therapy for neonatal candidiasis. Curr. Opin. Infect. Dis. 20(6), 592-597 (2007). (Pubitemid 350064180)
9. Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 44(11-12), 446-449 (2001). (Pubitemid 34131790)
10. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37(5), 634-643 (2003). (Pubitemid 37100802)
11. Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121(5), e1286-e1294 (2008).
12. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117(4), e711-e716 (2006). (Pubitemid 46071475)
13. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr. Infect. Dis. J. 26(8), 723-727 (2007). (Pubitemid 47424643)
14. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005). (Pubitemid 41170352)
15. Bochennek K, Abolmaali N, Wittekindt B, Schwabe D, Klingebiel T, Lehrnbecher T. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin. Microbiol. Infect. 12(3), 199-201 (2006). (Pubitemid 43379318)
16. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20(7), 1898-1906 (2002). (Pubitemid 34273282)
17. Smith PB, Benjamin DK Jr, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-b-d-glucan levels in children: preliminary data for diagnostic use of the b-glucan assay in a pediatric setting. Clin. Vaccine Immunol. 14(7), 924-925 (2007).
18. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821 (2008).
19. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol. 19(1), 253-259 (2001). (Pubitemid 32063503)
20. Allan BT, Patton D, Ramsey NK, Day DL. Pulmonary fungal infections after bone marrow transplantation. Pediatr. Radiol. 18(2), 118-122 (1988). (Pubitemid 18070759)
21. Taccone A, Occhi M, Garaventa A, Manfredini L Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr. Radiol. 23(3), 177-180 (1993). (Pubitemid 23220506)
22. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr. Radiol. 33(7), 453-460 (2003). (Pubitemid 36833728)
23. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348-359 (2007). (Pubitemid 46148777)
24. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007). (Pubitemid 46148776)
25. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49(11), 4536-4545 (2005). (Pubitemid 41552583)
26. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123(3), 877-884 (2009).
27. Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr. Infect. Dis. J. 29(5), 415-420 (2010).
28. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49(8), 3317-3324 (2005). (Pubitemid 41060577)
29. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27(9), 820-826 (2008).
30. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39(10), 1407-1416 (2004). (Pubitemid 39518200)
31. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351(14), 1391-1402 (2004).
32. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51(10), 3714-3719 (2007). (Pubitemid 47519363)
33. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48(6), 2166-2172 (2004). (Pubitemid 38691615)
34. Karlsson MO, Lutsar I Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53(3), 935-944 (2009).
35. Neely M, Rushing T, Kovacs A, Jelliffe R Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50(1), 27-36 (2010).
36. European Community. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of medicinal products for paediatric use http://serviziweb.unimol.it/unimol/ allegati/pagine/5762/ceci.pdf (Accessed 26 July 2010)
37. European Medicines Agency. ICH Topic E www.tga.gov.au/docs/pdf/euguide/ ich/271199en.pdf (Accessed 26 July 2010)